Novartis3d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Healio6d
Eosinophilic granulomatosis with polyangiitis remission achieved with benralizumab
Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...